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Maintaining Equilibrium Between Project 
Success and Team Well-being: 
Pharmaceutical Project Management 




Projects of all types bring with them their own set of challenges and risks. Those within the 
pharmaceutical industry are subject to heavy regulation, high risk of failure, and the 
requirement of having very specialised knowledge. High-pressure projects like this also puts 
much stress on the individual team members working to ensure the project’s success. In order 
to delve into what it takes to maintain equilibrium between project success in a timely and 
cost effective manner, and the well-being of the project teams themselves, this research takes 
a look at what are the common issues with these types of projects. Issues such as unrealistic 
timelines and budgets, unclear requirements, and inadequate resources, will be explored to 
determine what affect they have on the workers, and how might these issues be addressed in a 
structured and repeatable way, regardless of project type. 
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Pharmaceutical projects of all types are well-known for their reliance on specialised 
knowledge, their innovative nature, being heavily regulated, as well as having a high risk of 
failure (Chiou, et al., 2016). Like most projects, planning and control are critical functions of 
their successful management. According to (Pellerin & Perrier, 2018) this involves 
representing a project through a set of requirements, scheduling project activities, allocating 
project resources, analysing the various risks involved, evaluating time and cost performance, 
forecasting cashflow, etc.. The question arises then, as to what can be done differently in 
order to mitigate the higher levels of risk, and navigate through the various regulatory 
requirements while managing to maintain an acceptable success rate and prevent churn in the 
specialised workforce. 
 







Research Question(s), Goals and Objectives  
This research is on the use of the Stage-Gate framework for managing pharmaceutical 
projects, with a particular focus on an implementation to both deliver projects successfully in 
a high-risk and heavily regulated industry, and improve team morale, culture and motivation.  
 
This project aims to: 
• Identify and discuss the impact of heavy regulation on the success of a project and the 
well-being of the team 
• Identify project management frameworks in use in the industry 
• Discuss the benefits of Lean/Agile/Stage-Gate frameworks and how learnings from 
them might be adapted for use in pharmaceutical projects 
• Highlight correlations between team well-being and successful project delivery 
• Discuss improvements to team well-being and successful project delivery through 





Research Design Methodology  
This study is a qualitative research which is supported through a probing into academic 
papers and an interview conducted with an industry expert. The primary data has been 
collected using recent academic papers mostly from the last 5 years, but no later than 10 
years old. Research from different countries has been considered in order to reduce bias 
towards particular culture based implementations. Secondary supporting data has also been 
collected from websites, books, digital news sources, journals and university lectures. The 
literature review was conducted in September 2020, using research papers and slides from 
CCT College EBSCO, as well as Google Scholar. The interview was conducted in early April 
with an expert, having over 30 years’ experience in R&D, IT, construction, and PM 








Much time is spent in the initial planning phases of traditional projects, with complex and 
extensive requirements documents being drafted in negotiation with clients in order to 
understand their needs and make commitments for the delivery of the project. It is not at all 
uncommon for clients to request alterations to the initial plan however when, for example 
their own business needs or priorities shift. There is a consensus among researchers (Cooper 
& Sommer, 2016) and (Kuruvilla, 2019)that when this happens it can be very costly to make 
these changes, especially if the project is in the later stages of its development life-cycle. This 
often results in compromises needing to be made by the client, which is less than ideal from 
the clients perspective, as well as a drop in team morale, where they must re-do or disregard 
work that they have previously done. (Scolding, et al., 2020) mentions the importance of 
team morale in being able to effectively respond to developments in high pressure situations, 
and how regular retrospectives can help improve processes and increase efficiencies 
iteratively. These retrospectives normally happen at the end of a long project when using 
traditional management approaches, which means the benefits won’t be seen in the current 
project and issues that arise and bad practices can often persist until a project is completed. 
 
(Kuruvilla, 2019) also mentions that traditionally managed projects in the pharmaceutical 
industry often suffer from unrealistic commitments to timelines made in the initial planning 
stages. This naturally leads to situations where development teams are under pressure to 
deliver products before their ready, but regulatory obligations obviously don’t allow for this, 
and so deadlines are frequently missed. Allocation of resources is also an issue where 
hierarchical management structures introduce competing priorities of managers looking to 
reduce costs, and development team members requiring sufficient resources to reliably 
manage the throughput of work in progress (Cooper & Sommer, 2016). 
 
As its name suggests, Agile project management aims to tackle these issues that causes 
development to be slow and cumbersome. It does so by laying out a guiding set of principals 
in the Agile Manifesto to reduce wasteful processes with continuous improvement while 
increasing a team’s ability to adapt to changes through an iterative approach to development 
(DeBenedictis, 2019).  
 
Agile however, is often seen as fundamentally incompatible with regulated environments 




Other barriers to adopting an Agile approach to development, identified by (McHugh, et al., 
2012) are traceability issues, lack of up-front planning, and managing multiple releases. As 
such, many researches such as (Cooper & Sommer, 2016), (Batenburg, et al., 2015), (Jones, 
2020) and (Lechler & Thomas, 2015)  suggest that incorporating methodologies from the 
Stage-Gate framework is successful in addressing these shortcomings. 
 
It seems while there is a steep learning curve associated with the mindset shift needed to 
make the move to a more agile approach to project management, it is very likely to be more 
beneficial in the long run. With a simple implementation, and clear guidelines for gates and 
gate-keepers, it can be easier to pilot these new working methodologies in a way that’s 
flexible enough to empower team rather than restrict them, while still maintaining the 
important decision making stages to ensure regulatory compliance. With a set of guiding 
principles, it is then possible to scale the implementation to suit the needs of the team and 






Results (Research Findings) 
Stage Gate Methodology 
The Stage-Gate methodology is a widely used framework which, as the name implies, breaks 
projects into a series of stages and gates. The stages delineate different critical phases of the 
project which have their own requirements, risks, etc., and the gates in between every stage 
represent a period of review and due-diligence which aims to evaluate the viability of moving 
forward given the current state of the project and its environ. (Johnston, 2021) seems to agree 
with (Jones, 2020) description of Stage Gate as “The Quintessential Decision Factory” as 
both have argued that Stage-Gate projects have an increased speed to market and profitability 
rate over their non-Stage Gate counterparts, speeding up and energizing an organization’s 
projects (Johannesson, 2016). 
 
(Johnston, 2021), in this author’s interview with him, describes the use of the Stage-Gate 
framework in the scenario of a capital project for building a new facility for the production of 
pharmaceutical products. The Stage-Gate model for this example project can be seen below 
in Figure 2 and this example will be referenced throughout this research paper. 
 
Figure 2- Example Stage-Gate model for pharmaceutical capital project 
(Johnston, 2021) argues that the most important phases of this proposed Stage-Gate model, 




initial planning stages. In this case that would be the Strategic Planning and Concept Design 
phases. It is at these stages that fundamental questions are asked and decisions and estimates 
are made which will affect the entire project going forward to the point that provided these 
fundamental questions can be answered correctly, with sufficient time and due-diligence 
given to ensure such, that almost 50% of the potential benefit of a project can be secured after 
the Strategic Planning Phase. The additional benefit, up to 80% - 90%, can also be secured 
after the Concept Design phase provided it is done to a high standard and proper 
consideration is given to all the different ways of achieving what was laid out in the strategic 
design and the project team at this point performs the various costings and high-level designs 
in order to ensure they are choosing the most optimum option for the organisation (Johnston, 
2021). 
 
It is clear that with such a high value given to the planning phases that the sentiment is such 
that even if the project is poorly executed in the later phases, because there is a certainty that 
the correct path to completion was chosen, the impact of this is a lot smaller than it otherwise 
might have been. 
 
The stage-gate structure and approach help give project teams the granularity they need 
throughout a project, because at each gate-review step there is a cross-functional review team 
set up to ask two important overarching questions. 
 
The first question is “have we done everything we should have done in this phase to the 
correct standard?”. At the end of the concept phase, for example, the review team might look 
at whether or not they have produced all the necessary documents, have these documents all 
been appropriately reviewed and approved, has the industry expectations for deliverables 
been met, have the clinical trial timelines been benchmarked against the industry average, are 
the timelines or budgets set out to ambitious, and how much risk is being carried over into the 
next phase, etc. (Rocque & Viali, 2004).  
 
Next, the project team ask themselves “how well are we prepared for the next phase?”. This 
should take into account things like, have resources been appropriately planned, how is risk 
management going to be done in the next stage, how are clinical trials to be properly run, has 
a contract manufacturing organisation been lined up to take on the production of the tens of 





(Shah, 2017) mentions the importance of documenting such things and preparing them in a 
format for review at each gate so that they can be quickly used as materials for supporting 
decisions. This decision could be yes, we have sufficiently completed this stage and are ready 
to move to the next stage, confident that there is minimal risk. It could also be no, as, for 
example, the gate review team may feel that some critical components of the current phase 
have not been completed. The outcomes of this could be that the project will be put on hold 
until those failings have been sufficiently addressed, or else they might decide to continue on 
to the next phase at-risk, but putting into place agreements that those components must be 
properly completed within the next two weeks, for example. 
 
It is evident that taking this approach, 
it empowers project teams to take a 
well-documented body of best 
practices and regulatory requirements 
and insist that due diligence is done at 
each stage of the process. (Johnston, 
2021) states that ideally, this allows 
for what’s referred to as “unhindered 
execution” with minimal changes to 
the plan. Oftentimes strict measures 
will be put in place that after a certain point no changes can be made to a project’s scope 
without going through an obscene amount of red-tape in order to prevent scope-creep and 
minimise risk by taking away this avenue for potential costs and scheduling impacts 
altogether. It also helps with communication as everyone involved in the project should be 
very clear about what needs to be done. 
 
Internal factors aren’t the only consideration during a gate review however. (Iqbal & 
Suzianti, 2020) also identifies that pharmaceutical companies emphasize the external risks of 
the regulatory environment and other competitors during the gate review process.  
   
While Stage-Gate by no means prescribes to any specific organisational structure as such, 
some organisations have arrived at their own optimum structures in order to manage the 
complex nature of these projects with a need for specialised skillsets. These structures 




revolve around three roles at their core; the Sponsor, the Project / Program Manager, and the 
Facility Owner / Lead End User. These three core roles have been found to work well with 
most project types (Johnston, 2021). 
 
It is the Sponsor who is accountable for ensuring that the investment into the project is not 
only initially viable, and that the benefits proposed can actually be achieved, but that these 
benefits continue to be viable throughout the project, right up until its completion and launch.  
 
In the strategic planning phase, the Sponsor will be lead the drafting of the Business Case 
document which details the reasons for a particular investment being made. At each of the 
gate reviews, the review team will always go back and check that the business case for the 
project is still valid. Consider the capital project example again, and imagines at one of the 
gate reviews about halfway through the project it is discovered that there are three other 
competitors after making a similar vaccine, and that they are at a further stage of their clinical 
trials and have achieved better results in their trials than ours. The Sponsor will be in charge 
then of determining what the possibility is that our capital project can be completed in time in 
order to be first to market, or if it is reasonable that the efficacy or use case of our product 
can distinguish us from our competitors such that it is still a viable option to continue with 
the capital project unhindered. This resonates with what is happening at the time of writing, 
as we see multiple pharmaceutical companies promoting their vaccines for the COVID-19 
virus with varying efficacy rate, or different requirements for correct storage leading the 
some being more feasible than others in certain circumstances (Dunleavy, 2021). 
 
At this point, it may not make sense to continue investing into the project, and it may be 
better to pause and re-evaluate, or else to cancel the investment altogether if the benefits 
initially planned are no longer valid and the return on investment has been drastically 
reduced. 
 
With respect to the other two major roles, the Facility Owner (capital projects) otherwise 
known as the Lead End User (product / service projects) is responsible for the future state of 
the project, for example, what the new facility being built should look like, or what the go-to-
market strategy is for the new vaccine. The Project Manager then is responsible for helping 
the Facility owner achieve that future state, by managing the various contractors and 





These division of labour into different categories correspond with what (Brandl, et al., 2018) 
called the “macroplanning horizon” of Stage-Gate, where they divide a project into three 
planning levels: strategical, tactical, and operational with a different methodology for 
tackling each developing a “healthy tension” between fixed and iterative planning. (Cooper & 
Sommer, 2016) takes this further in suggesting a new high-level management model called 
Scrum-Stage-Gate. 
 
Both (Aristodemou, et al., 2020) and (Cooper, 2007) point out that particular projects, like 
pharmaceutical ones, are fragile, unique, and knowledge-built. This leads to the 
mismanagement of such projects, and these researchers advocate for Stage-Gate to better 
manage. (Sabbaghi & Allahyari, 2020) puts it well by saying: 
“risk management is inevitable, and it also exists in unorganized projects in an 
unsystematic and intuitive manner. The point is to achieve the most positive results 
from the risk management by making it a systematic activity.” 
This splitting the work into three categories is further supported by (Kuchta & Skowron, 
2016) where they suggest concept control structures of Product Breakdown, Work 
Breakdown, and Organisation Breakdown. It may be evident to the reader that these 
structures align somewhat with the responsibilities of the three core roles mentioned 
previously. 
 
One of the topics this research paper wants to address was regarding the culture of 
pharmaceutical projects, how that can be enhanced, and whether the regulatory environment 
makes it more difficult for the project culture to develop positively. 
 
(Johnston, 2021) finds that, especially for those who are used to working in pharmaceuticals, 
and have grown up with regulatory expectations ingrained in the culture, it is no different 
when they begin to work as part of a project.  
Where this is not the case, however, and the regulations can become a problem, third-parties 
with no experience working in pharmaceuticals are brought in to the project. This is even true 
where the third-parties have experience in other heavily-regulated industries, such as nuclear 




styles, with some being very prescriptive, and some being more conceptual and open to 
interpretation. As such, where these types of partners are onboard, it is even more important 
to ensure that there is a solid communication plan so that everyone is operating under the 
same specific understanding of the requirements, and that this is reviewed on a regular basis 
to ensure there is no deviation between the teams understanding. 
 
Failing to complete the necessary due diligence and following the laws and regulations laid 
out be each of the regulatory bodies with authority over the markets the product will be 
operating in can have an effect on the future trust of owners, partners and employees, and so 
the risks of such failures should not only be considered in the short term, but also for the at 
the “big-picture” level over longer time frames (Kendrick, 2015). 
 
(Sangshetti, et al., 2017) notes that the FDA inspection team, during pre-license or 
preapproval inspections under a QbD (Quality by Development) concept assess the 
implementation and efficacy of the process design submitted as part of the application, as 
well as the successful transfer of knowledge between the design phases through to the 
manufacturing ones. 
 
Regulatory affair organisations however will help a project team to understand the regulatory 
requirements and, due to the strict nature of how these regulations must be followed, they 
often actually help to clearly define the structure of a project and all the necessary stages that 
the new product lifecycle needs to go through (U.S. FDA; CDRH; CBER, 2002). 
 
The overarching stages of our example project would be for the research and development of 
a new vaccine. These would surely be much different than those for the capital sub-project of 
building the facility to produce the vaccine. As such, there would be a whole other set of 
regulatory requirements that need to be considered, and a completely different body of work 
that needed to be done. The Stage-Gate model however can be adapted so that it still provides 
the same confidence in planning and executing the project with minimal risk. 
In this example, the first stage would still be strategic planning, with the aim being to define 
the requirements such as, the market(s) in which the product will be launched, the data that 
must be collected and submitted to each of the regulatory agencies in those markets, how 




submissions, should applications be made for any rapid-review schemes with the agencies, 
how those can be applied for, etc… 
The following stage then might involve pre-clinical work, and then the subsequent three 
stages would delineate different phases of clinical trials, with the proceeding stage being for 
filing applications with the various regulatory agencies, and so on and so forth.  
 
So while there are stark contrasts between the two example projects, by adopting the stage-
gate process, a project team can be confident that they understand the requirements and 
periodically address the risk to ensure adequate resources are made available to keep the 
project within budget and timeframe, or to adjust the budget and timeframe of the project 





Top Causes of Stress for Project Teams 
According to (Johnston, 2021) there are three main causes of stress on project teams that 
stand out as warranting the most concern and are often ignored to the detriment of a project’s 
success and the well-being of those involved. These are unrealistic timelines and budgets, 
unclear requirements, and inadequate or poorly managed resources. 
 
Beginning with unrealistic timelines and budgets, this is a symptom that can be found across 
projects of all types. What is often the cause of this seems to be either insufficient, or in some 
cases a complete lack of strategic planning. (Edgett, 2018) states that the failure or success of 
a project is more often than not determined before it has even begun development, as what 
they call the “critical upfront activities” that define the attributes, features and benefits of the 
project will either have succeeded or failed in lining the path to success at the end of the 





Chart 1- Project Stage Vs Influence on Project Success 
amount of time and resources should be spent on doing the initial stages of a project correctly 
where the influence on the success of the project is much higher Chart 1, and the cost of 
change is significantly lower Chart 2. 
 
Chart 2- Project Stage Vs. Cost of Change 
During the interview, (Johnston, 2021) recalls being called in to advise on many projects 
where someone might have had a good idea, and there was an opportunity to do something 
with it. They might have then, for example, called the head of engineering on a site advising 
they were interested in making an investment. After giving very little detail on a set of 
hypothetical requirements, they would ask for a quick tender to be drafted up within a very 




agree to do so, and then rush to put together a high-level proposal, with many huge 
assumptions made regarding cost, timelines, and risks. The issue then is when the company 
would come back and advise that they will proceed with the proposed project. The site is then 
held to these unrealistic budgets and timelines, and given a “fait accompli” where they are 
expected to deliver on a project that is likely doomed to fail from the beginning. This is 
where stress and difficulties very much come to the fore as in a situation like this the workers 
know that the project is not credible or realistic, and that they can’t change it, or that they 
must bear with it and potentially overwork themselves as the reputation of the site is at stake. 
 
While this example is somewhat contrived, the sentiment stands that where Strategic 
Planning isn’t done, options aren’t looked at, no benchmarking is done, it would not be 
uncommon for the project to reach a certain stage before anyone realises the cost of the 
project has gone up 50%, and the project team is playing catch up throughout (Johnston, 
2021). (Kendrick, 2015) describes these scenarios as “ready-shoot-aim” tactics where the 
work is begun before there is an understanding of the scope. This research conducted a case 
study where a project had begun while 75% of the requirements were initially unknown by 
the team and what had been initially in scope was never even signed off by upper 
management. This lead to numerous regulatory obligations not being met, something which 
was not identified until the mid-project review. 
 
In order to avoid situations like this, (Johnston, 2021) advises that regular “Risk Workshops” 
be conducted during each of the individual phases in order to understand how the project is 
evolving. By doing this at each stage, a better understanding can be gained as to how risks 
identified in previous stages have either persisted, or been mitigated away. It’s very difficult 
for teams to identify and understand the full extent of risks for a project, especially one that 
may span a number of years. Certain individuals with a lot of experience might have the 
ability to advise on risk based on past experiences, however, each project brings with its own 
unique set of challenges and so regular periodic risk workshops, and a well-defined risk 
management plan can assist greatly in simplifying and anticipating what might happen in the 
coming stages as designs mature, requirements are further defined, and as more and more 
workers and organisations join the project. This last point also brings with it a benefit, as with 
more parties joining the project comes a pearl of greater collective wisdom regarding 
specialised tasks. By doing risk workshops across the project and iteratively at each phase 




the core project team. Risk registers can also be updated to prepare as input into gate reviews. 
This becomes a powerful knowledge-bank that can be very easily assessed by those in charge 
of managing the project’s schedule and cost so that mature discussion can be had about the 
upfront cost of mitigating risks, or the subsequent cost of failing to do so (Johnston, 2021). 
 
The second cause of stress, unclear requirements was already touched on above, however, 
this author feels it warrants further discussion. The onus is not only on management to 
provide clear requirements, but also on those executing the tasks to ensure that they 
themselves understand the requirements. (Drakeman & Oraiopoulos, 2020) mentions a 
problem that big pharma has in that the signal to noise ratio is massive. And that getting the 
right information to the right small number of people at the right time is very difficult given 
the large number of resources and complex information filtration systems that are often put in 
place. They later go on to say that a parallel search process, where two parties are operating 
off of different understandings of the one requirement is likely to lead to a large number of 
failures. 
 
This can sometimes be found when dealing with third-party contractors that might approach a 
project in a way that suits their needs, rather than the needs of the project or the contracting 
company. Clear, unambiguous requirements can help circumnavigate these types of issues.  
 
(Kendrick, 2015) talks about change being unavoidable as legitimate needs are uncovered 
later in a project, and how even if productivity is unaffected, there is the potential for discord 
on the team. A project’s success tends to rely on the teamwork. The conflict, strained 
relationships, low morale, and lack of cooperation that arises from the absence of good 
teamwork can have a detrimental effect on the success of a project. This is partly the reason 
why many stage-gate projects tend to tightly lock the scope of a project after the strategic and 
concept phases have completed. (Johnston, 2021) advises that red-tape can also be 
purposefully put into place to make it extremely difficult to make any changes or introduce 
anything new into the scope of the project in order to avoid costly late changes Chart 2 and 
project delays. This is easier said than done, however, as being able to commit to a project 
scope so strictly requires great maturity in the organisational culture and very strong 
leadership so that people can trust that the ones making the decisions have the best interests 





(Sabbaghi & Allahyari, 2020) define in their research three types of supply risk. Process risk, 
when the product is not produced to the specified deadline, quantity or quality. Demand risk, 
when the demand for a product outweighs its availability. Control risk, when the quality 
control is not sufficient. As a project grows so too does the level of uncertainty around things 
like resource allocation, which leads to the third main issue of stress for project teams, 
inadequate resources. 
 
While the above is specifically to do with the product itself being a resource, which can put 
stress on supply teams, customer relationship managers, factory staff, etc., this is not the only 
scenario where inadequate resources can be an issue. At the beginning of a project, especially 
during the concept phase, (Johnston, 2021) suggests that it is vital to the success of the 
project that the project team has access to the specialists it needs who have the expertise to 
thoroughly understand the new design, the product, and the best way forward for the project. 
This however, is invariably difficult as specialists such as this will nearly always be required 
by the organisation on other tasks at the same time. 
 
Going back to the capital project example. If the specialists are, for example, only contracted 
later on in the project, it is likely that they will be missing the very specific knowledge of 
how this particular site operates, how and to what standard things should be done, how 
maintenance must be facilitated, etc... This goes back to what was mentioned before about 
front-loading projects. The insights from these specialists into the commercial viability of a 
project are essential and ensures a better transition between stages as they might identify 
opportunities for the project to be protected through patents, trade secrets, or have special 
access to raw materials, opening up new possibilities, etc. (Cooper, 2007). As such, before 
the project even begins there should be commitments in place that the necessary people will 
be released to the project for a sufficient amount of time as without sufficiently diverse 
perspectives with regards to resource allocation, the “innovation funnel”, as (Drakeman & 
Oraiopoulos, 2020) puts it, becomes too narrow too quickly for it to be able to achieve the 





It can be difficult, however, to manage resources without the proper supply and demand 
metrics in place. The methodologies a project uses in order to measure its various 
components and track progress should be clearly defined in the Progress Measurement 
section of the Project Execution Plan. The requirements for metrics being tracked and how 
they are analysed will invariably change between each stage of the project, as well as for each 
discipline, or resource category. Consider a team of electricians working at one of the later 
stages of the capital project laying cables. Their performance might be measured using meters 
of cables laid per day. This metric could also be used to track the burndown of the cabling 
resource, with some adjustments made for waste. However, this metric would make no sense 
for a team of clinicians conducting the clinical trials. A project control team is usually put in 
charge of determining the most appropriate way of taking, recording, and analysing such 
measurements. Part of this work can also be to procure any systems that may be required to 
store and visualise this data appropriately. Common system requirements might be the ability 
to produce burndown charts, progress or earned-value curves, schedules, and the ability to 
monitor progress against these schedules, as well as to perform various aggregations atop the 
different metrics and schedules. Once these metrics are in place, resource levelling methods 
which aim to reduce peak requirements and minimise fluctuations in resource utilization 
becomes a much simpler process (Pellerin & Perrier, 2018). 
 
 




Giving a Voice to the Team 
It has been well documented in the IT industry how Agile practices, such as retrospectives 
sessions, serve to give a voice to the individual members on project teams, allowing them to 
contribute to developing better processes and team methodologies in the spirit of continuous 
improvement (Scolding, et al., 2020). This research not only boosts team morale, but also 
addresses one of the major concerns (Kuruvilla, 2019) pointed out in their research which 
was accountability. It is said here that traditional pharmaceutical project teams with 
hierarchical management structures face this issue where members are afraid to speak up 
about mistakes, delays, or future risk. 
 
In order to foster a similar organisational culture of transparency and accountability without 
reprimand, pharmaceutical Stage-Gate teams have adopted the practice of “Lessons Learned” 
sessions, which can be a part of daily or weekly meetings, needs dependant, with a larger 
session conducted towards the end of each stage. This helps prepare a very useful bank of 
information that can be used as input into the gate reviews so that knowledge can be rolled 
over into the next stage, but more importantly, on an individual level, it is an opportunity for 
team members to reflect, and for kudos to be given for jobs well done. By not only focussing 
on the negative, but also on the positive like this, the project team can create a body of best 
practices, as well as problem solutions which can be carried forward into the next project 
(Chiou, et al., 2016). High-functioning companies even go so far as to ensure these lessons 
learned are shared between projects so that different project teams that could be based around 
the globe can learn from each other’s successes and failures without having to go through 





Conclusions and Further Work References 
The successful management of a complex pharmaceutical project and the well-being of its 
project teams is less correlated to what was originally perceived as a struggle against strict 
and heavy regulations, but more so with the maturity, transparency, and timeliness by which 
decisions are made. This such that learnings on these matters in any type of industry project 
can well be applied to pharmaceutical projects, with the caveat that their specific 
characteristics are taken into account. A well-defined project with mature leadership, rigorous 
planning and monitoring, as well as modern communication processes which promote trust 
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Week 1 Research literature 
Week 2 Write up initial findings 
Week 3 Review, and conduct further research 
Week 4 Design questionnaire, pre-interview steps (deliver questions, 
consent, etc.) 
Week 5 Conduct Interview & Organize interview context 
Week 6 Review, and conduct further research 
Week 7 Finalize project content 
Week 8 Finalize document formatting & prepare presentation 
Week 9 Finalize & deliver presentation 
 








When conducting the initial literature review, while there was a lot of material on project 
management, and delivering projects in the pharmaceutical industry, a lot of the information 
was extremely specific and it was difficult to generalize some of the research to infer industry 
best practices in-use. As such, the focus has shifted more towards the benefits of the 
frameworks themselves, and how they can be applied to challenges within the industry. 
 
This research will also include an interview with an industry expert (lead project manager 
consultant within the pharma industry) in order to make up for any industry specific 




interview ethics, consent, and availability of the interviewee. A consent form has been 
drafted, and research has been done into ethical considerations to ensure I am well informed 
as to how best to conduct the interview and handle information and communications 
pertaining to the interviewee. The interviewee has also made assurances regarding their 
availability; however, it is understood that this can never be fully guaranteed, due to a good 
relationship with the interviewee it might be possible to arrange for a suitable substitute if 




Appendix B: Interview Questions  
 
Question 1 
Themes: PM framework / managing risk & failure / delivering value 
Why choose Stage-Gate for pharma projects over other PM Frameworks such as 
Agile, Lean, or PRINCE2? 
• How does stage-gate help with managing risks? 
• When choosing stage-gate, are you also choosing a trade-off between speed 
of delivering value and reducing risk? How does this affect the profitability of 
projects? 
• What is the main driver of cost associated with pharma projects? How do you 
approach minimising these costs as well as the risk of going over budget? 
 
Question 2 
Themes: positive team culture / managing risk & failure / communication / heavy-
regulation 
A growing trend is observed in other industries where a focus is being put on team 
culture and empowerment, as well as overall employee well-being as it has been 
found to boost productivity and innovation while also having a positive affect on 
reducing stress, burn-out and turnover of employees. Is a similar focus given to this 
in pharma products? If so, what are some of the strategies implemented and have 
the results been positive? 
• What are the main points of stress / difficulty for teams / individuals within 
pharma projects? 
• How does the heavily regulated nature of pharmaceutical projects affect team 
morale / performance? Is it difficult to maintain employee motivation when 




Themes: positive team culture / balancing speed and quality / cross-functional team 
/ delivering value 
Does the structure of teams, leadership, and reporting hierarchy differ much in a 





• Are cross-functional teams used? How are teams generally structured? What 
is the purpose of the chosen team structure? 
o Are there any improvements that might be made to team structures 
that might improve the speed at which projects can be delivered using 
better communication strategies etc.? What are some of the roadblocks 
in implementing these new structures? 
• Retrospectives in Agile and Lean are vital to continuous improvement. Retros 
provide huge benefits to teams allowing them to fine-tune processes, flag 
risks, reflect on what went wrong. They can also help greatly in boosting team 
morale as everyone gets a chance to put their suggestions forward. They are 
particularly useful with cross-functional teams where issues with 
communication, handovers and over/under-utilization can be flagged. It is 
much easier to see how this type of ceremony fits in with Agile projects that 
tend to be shorter and more iterative, and so my question is, do you utilise 
any form of retrospectives throughout a pharma stage-gate project, and if so 
when are the best times do conduct them? 
 
Question 4 
Themes: best practices / heavy-regulation / PM framework / managing risk & failure 
How do you go about determining the stages, gates, and decision criteria for a 
project? 
• At what stage of the project are these generally decided upon? 
• Who is responsible for making the above decisions? 
• Is the stage-gate model tailored specifically to every pharma project or are 
their templates that are used for different categories, for example “Drug R&D”, 
“Medical Device Development”, and “Regenerative Medicine Research”? 
 
Question 5 
Themes: Delivering Value / Managing Innovation / Measuring Performance 
Other frameworks like Agile & Lean put an emphasis on development driven by the 
needs of the consumer / client, iterating on the product in order to meet their 
changing needs or adapt to their feedback. On pharma projects, which are more 




• How is performance best measured? Are there specific metrics you heavily 
rely on in order to track performance? 
• How do you determine value and priority when considering a project? 
• Do you use any frameworks or methodologies for managing innovation such 













Question 1 -  PM framework / managing risk & failure / delivering value 
 
In our company, we only use the Stage-gate project management framework instead of 
others, as well as a standard for us to follow and operate every programme. The programme 
range could be very wide, such as maintaining capital environments, improving IT 
sectors,  erecting a new factory, planning a new programme, R&D for new products, and 
daily project management practices in process. Stage-gate is a framework with a fast track, 
which suits a team / company has a considerably tight time limit, bustling working 
environment, receives order from many clients at the same time, and special designs are 
requested, while the pharmaceutical industry operates like this. 
 
And the reason we use Stage-gate is that it is more flexible to adapt every new idea from 
different sectors; it is well structured to follow easily; once the project is well planned in the 
early stages, it has a fairly high percentage to reach the project goal and make great benefit to 
the firm.  
 
This is a basic framework we use to explain to our clients in the company. Instead of 5 stages 
and 4 gates, this is simpler to give a process baseline for explaining the elements are needed 
in a project.  
As I mentioned earlier, the first two phases which are “Strategic planning” and “concept” are 
the most vital fundamental stages in the whole project. If the team can come up a plan with 
some great influences, for instance, certain resources, understanding customers/shareholders 
requirements, and drafting the project abide by EMA/ FDA/ Clinical Trial standards…etc, 
above components would lead the project operate into a right direction and likely to have 80-
90% successful rate to bring benefits back to company.   
 
 There were a few past clients we had, while they were concepting the project, they didn’t 
consider all the requirements, follow the company/ government /industrial regulations, or 
didn’t manage the resources very well. When the project moved on the mid-stage, more 
problems and issues had shown, they had to pause the action, hire more people and went back 




Question 2 - positive team culture / managing risk & failure / communication / heavy-
regulation 
 
Risk management is vital in every phase/stage/gate which has the same duty as an 
administrator. We often use “Risk Workshop” to identify the things that are likely to derail 




matureness of team performance to find defects/weakness/problems/ blind spots/boundaries.  
By doing the risk management across each phase, update the registers, comparing with past 
risk logs, and weighing out the impacts of risk. The results from the risk workshop are 
reflecting the actual workforce and performance from the project, it could help the manager  
forecast the further risk might happen, how much budget is needed to add on and try to 
mitigate the risk, reduce the potential cost.   
  
 
In this case, sometimes, heavy regulation is actually a good helper as a best practice guideline 
to let the project progress smoother. The regulation means a standard people must follow; a 
structure people must take; and expectations people must achieve.  It helps the team to define 
the necessary steps/elements/requirements that need to be kept or removed to meet market’s 
expectations. For example, many pharma companies are trying to produce vaccine and 
relative medicines/devices for Covid-19 usage. Covid-19 is a new virus which has higher 
difficulty to do background research. At this stage, One of the FDA/ ICH/ IOS 9001/ EMA 
guidelines would help the new project work with a benchmark, how they need to operate the 
product life cycle and ensure the product would be qualified before launch.  
The Stage-gate provides a structured discipline around the project, compose the requirements 
and external potential impactors, and make sure every member understand their duties, cross-
function, equipment checking, remain the resources supply steadily and being critical on 
every stage/gate review which can save more time for further phases. 
  
There are 3 things we found out that have brought profound negative impacts in the project 
process in general, which are unrealistic timeline & budget, unclear requirements and 
inadequate resources.  Without clear definitions/record details/timetable/cost, the difficulties 
have increased to deliver the information and the team has to come back forward to redo the 
same tasks over a few times; overall, unclear requirements affected the effectiveness. 
 
 
Question 3 - positive team culture / balancing speed and quality / cross-functional team / 
delivering value 
 
Frontline loading has a key job to mitigate the risks, conflicts and reduce the late changes. 
As a manager or project leader, there are some tips can help, for instance, encouraging all 
team member to involves decision-making, creating and analysing information; spending 
more time to repetition of information and make sure the members fully understand it, it 
would have a better result compare with cramming numerous information in a short period of 
time; knowing your team members' preference in learning type, some people are doing better 
in individual learning, some people have greater performance while they are paired with 
others. 
 
We didn’t do retrospectives activities in our company, however, we do weekly briefing and it 
has worked out perfectly for us. By concise information to call out the good/bad findings, key 
points of learnings and input key notes into gate reviews. Those activities would help the 





We often use a phrase “Go Slow to Go Fast” to remind team members or managers that a 
well-structured project management proposal and comprehensive plan is crucial. The 
expertise, specialties, shareholder, sponsors are the people who lead the early phases of the 
project which are not many but very important, they really need to take time to find a balance 
between company culture, market demand, regulations, recruiting good people, managing 
available facilities and stable supplier with high quality materials to conduct the project and 
guide the team to achieve success. As many examples, most reasons for failure in a project 
are  total cost over the budget, return back to the previous stage to redo partial elements, 
didn’t follow certain regulation guidelines and find out some defects in the design. Those 
factors would lead the project to either spend more time, raise budget to fix the issues or 
totally cancel the project. 
 
 
Here I would like to point out that positive company culture and strong leadership are 
important to help the team operate the project abide by the PMI, minimise the unrealistic 
factors and adapt the challenges. Especially during the “concept” phase, a nice leadership 
would create an open communication platform, pay attention to every sectors’ advice and 
voice, find the agreements in between and well-deliver to the design time.  
 
 
Question 4 - best practices / heavy-regulation / PM framework / managing risk & failure 
 
Project Execution Plan(PEP) from PMBOK is highly recommended to use, the most basic 
one but suits for every project, and it is also the one we use for risk management. It includes 
the project definition( Introduction background and history), project objectives, project scope, 
project interfaces, project assumptions, project governance, key roles and responsibilities, 
project responsibility matrix, and project schedule (Schedule hierarchy) must be documented 
clearly and in order. With a standardized record and easy-read PEP template, the whole team 
would know what are their own duties and who would be the to-go person when they have 
questions. As I mentioned before, PEP would be vital for early stages(Concept), it guides us 
to know how many risk workshop are needed, the bast practices from regulations, illegal 
items, facilitate factors, when would the reported risk be solve and closure it.   
Not only can finding blind spots easier but also can improve the communication system, 
especially when two different background sectors work together.  
It sounds easy but not every project does have a clear PEP template to follow. 
 
 
Question 5 - delivering value / managing innovation / measuring performance 
 
As I mention in the previous question, PEP would be the one to measure the team 
performance. Another meth we use in the company is similar to the Burndown Chart. 
Firstly,  making up a table(graph) with the goal lines; secondly, record every steps or results 
in the project and numerate it ; thirdly, uploading the operationally data into the table with 




in between. Using this method can easily see which gate/phase/step has issues, who is in 
charge of the task, and how the team should avoid the same issue for the future.  
 
 
 
 
